What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Kiniksa Pharmaceuticals International, plc KNSA EV / EBITDA

EV / EBITDA at other companies

Ligand PharmaceuticalsLGND

30.3×—

Catalyst PharmaceuticalCPRX

7.4×-1.4×

Mirum Pharmaceuticals, Inc.MIRM

1,820.6×—

Arcutis Biotherapeutics, Inc.ARQT

125.8×—

AlkermesALKS

30.8×+18.8×

Neurocrine BiosciencesNBIX

16.4×-5.2×

Other financials

Income statement

See full

Revenue$214.3M+55.5%

Gross profit$193.5M+61.3%

Operating income$29.3M+121%

Net income$22.6M+165%

EPS (diluted)$0.27+145%

Balance sheet

See full

Cash & equivalents$190.0M+20.9%

Total debt$9.0M-9.0%

Total equity$605.7M+32.4%

Total assets$825.3M+37.7%

Cash flow

See full

Operating cash flow$50.2M+125%

CapEx$161.0K+62.6%

Free cash flow$50.0M+125%

Valuation

See full

Market cap$4.24B+128%

Enterprise value$4.06B+139%

P/E58×—

P/S5.6×+1.8×

Profitability

See full

Gross margin89.3%+3.5pp

Operating margin12.4%+10.2pp

Net margin9.7%+7.6pp

FCF margin21.8%+12.2pp

Returns & leverage

See full

Return on equity13.7%+11.3pp

Debt / equity0×0.0×

Current ratio3.8×+0.1×

Where this comes from

Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.

enterprise value/ebitda=36.9×

Based on the most recent quarter.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's EV / EBITDA?: Kiniksa Pharmaceuticals International, plc (KNSA) reported EV / EBITDA of 36.9× in Q1 2026.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.